Meloxicam (MLX), a nonsteroidal anti-inflammatory drug belonging to the oxicam family, is commonly used to alleviate inflammation and pain. However, MLX's limited solubility and subsequent low bioavailability necessitate the development of innovative formulations. This study aimed to improve the dispersibility and stability of MLX by incorporating it into a self-microemulsifying liquid drug delivery system (SMLDDS) and subsequently converting it into a solid dosage form, specifically capsules